Peer review of Pfizer COVID-19 vaccine data confirms 100% effectiveness in adolescents
A new study published in the New England Journal of Medicine is confirming Pfizer’s claims of the high levels of effectiveness among adolescents of its COVID-19 vaccine. The study, which looked at 2,260 adolescents between the ages of 12 and 15, observed 100% efficacy in the group, with a favorable safety and side-effect profile. The authors conclude that the Pfizer vaccine produces a greater immune response for adolescents than it does in young adults.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…